Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says
Wave Life Sciences' (WVE) new data from its RestorAATion-2 study of WVE-006 for Alpha-1 antitrypsin deficiency, or AATD, was in line with expectations and supports its competitive profile, Wedbush said in a Tuesday note.The firm said the new data, from the 400-milligram multidose group and 600-milligram single-dose group, continues to demonstrate good consistency.Wedbush said the company provided additional evidence that supports the restoration of the endogenous regulation of AAT protein production by WVE-006, including two additional cases of an acute phase response.The firm said that feedback from the US Food and Drug Administration in mid-2026 could provide the company with an accelerated approval pathway.The firm has an outperform rating on the stock and a $15 price target.Price: $6.58, Change: $+0.18, Percent Change: +2.81%
